classification of high-risk mutations in mds
Published 2 years ago • 112 plays • Length 10:18Download video MP4
Download video MP3
Similar videos
-
5:38
the molecular and clinical classifications of mds
-
4:42
a practical approach to the classification of mds
-
2:12
allosct for aml with mds-related features as per the icc and who 2022 classifications
-
0:58
risk stratification in mds
-
3:01
the role of piez01 variants in patients with mds
-
1:40
mds 2023 highlights: classification and risk stratification systems & progression from ch to mds
-
7:54
patient/caregiver stories - living with mds
-
6:17
classification and prognosis in mds
-
4:28
understanding myelodysplastic syndromes (mds)
-
0:55
the use of ngs to better risk stratify patients & identify druggable mutations in mds
-
1:51
factors driving the transformation of chip to mds
-
1:29
automated tool for mds classification using the who & icc classification systems
-
11:33
treatment algorithm for low-risk mds
-
4:25
the challenges with accurately diagnosing and risk-stratifying patients with mds
-
1:25
prognosis and treatment in high-risk mds
-
1:30
the prognostic value of patient-reported outcomes in mds
-
3:10
the role of ngs in mds diagnosis
-
3:11
clinical characteristics of h-mds
-
2:02
unmet needs in high-risk mds and future therapeutic strategies
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
2:31
updates in the diagnosis, risk stratification & treatment of aml: who, icc, and eln classifications
-
5:14
prognostic value of the updated icc and who classifications for mds